-+ 0.00%
-+ 0.00%
-+ 0.00%

Dogwood Reaches 50% Enrollment In Ongoing Halneuron Phase 2b Trial

Benzinga·02/02/2026 13:39:47
Listen to the news

 - Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron® treatment to be well tolerated -